Watch for the First Oral GLP-1 Agonist, Rybelsus, During Transitions of Care

November 2019

Semaglutide (Rybelsus, reh-BEL-sus) will be the first ORAL GLP-1 agonist for type 2 diabetes...it's a tablet version of injectable Ozempic.

Glucagon-like peptide-1 (GLP-1) is inactivated in the stomach.

That's why other GLP-1 agonists...dulaglutide (Trulicity), exenatide ER (Bydureon), liraglutide (Victoza), etc...are injected.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Table of Contents

Pediatrics Don't Treat Pediatric Patients Like Little Adults
Heart Failure Consider Nuances to Optimize Acute and Chronic Heart Failure Treatment
Surgery Don't Add Peri-Op Stress-Dose Steroids to All Patients on Chronic Steroids
Hematology & Oncology Know When to Use Different Immune Thrombocytopenia (ITP) Treatments
Heart Failure Put the Use of SGLT2 Inhibitors for Heart Failure In Perspective
Hepatitis C Consider the Many Drug Interactions With Hep C Antivirals
Med Safety Address Patient Concerns About Impurities Found in Ranitidine and Other Meds
New Drugs Compare Baqsimi or Gvoke With IM Glucagon for Severe Hypoglycemia
HIV & AIDS Be Ready to Manage HIV Pre-Exposure Prophylaxis (PrEP) Meds on Admission
New Drugs Watch for the First Oral GLP-1 Agonist, Rybelsus, During Transitions of Care